DNA Plc's Interim Report January-March 2017: DNA's year

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
58
DNA Plc's Interim Report January-March 2017: DNA's year started strongly - net sales and operating result grew in the first quarter

DNA PLC STOCK EXCHANGE RELEASE 21 April 2017 at 8:00 AM EET 

Unless otherwise stated, the comparison figures in brackets refer to the corresponding period in the previous year (reference period). Figures are unaudited.

January-March 2017

  • Net sales increased 5.7% and amounted to EUR 213.4 million (202.0 million).
  • EBITDA increased 9.7% to EUR 65.9 million (60.1 million) or 30.9% (29.8%) of net sales.
  • The operating result increased 14.9% and was EUR 28.9 million (25.1 million) or 13.5% (12.4%) of net sales.
  • The mobile communication subscription base grew 3.8%, totalling 2,732,000 (2,632,000).
  • Revenue per user (ARPU) for mobile communications amounted to EUR 17.8 (16.4).
  • The mobile communication subscription turnover rate (CHURN) was 21.0% (13.6%).
  • The fixed-network subscription base (voice, broadband and cable television) grew slightly and was 1,120,000 subscriptions at the end of March (1,112,000).

DNA's outlook for 2017 remains unchanged

DNA's net sales are expected to remain at the same level and the comparable operating result is expected to improve somewhat in 2017 compared to 2016. The Group's financial position and liquidity is expected to remain at a healthy level.

Key figures

EUR million 1-3/2017 1-3/2016 Change, % 1-12/2016
Net sales 213.4 202.0 5.7% 858.9
EBITDA 65.9 60.1 9.7% 236.3
  % of net sales 30.9% 29.8%   27.5%
Comparable EBITDA* 65.9 60.1 9.7% 247.1
  % of net sales 30.9% 29.8%   28.8%
Depreciation, amortisation and impairment 37.1 35.0   145.0
Operating result, EBIT 28.9 25.1 14.9% 91.2
  % of net sales 13.5% 12.4%   10.6%
Comparable operating result* 28.9 25.1 14.9% 102.1
  % of net sales 13.5% 12.4%   11.9%
Net result before tax 26.6 22.7 17.2% 81.7
Net result for the period 21.2 18.2 16.7% 65.2
Return on investment (ROI), % 12.5 10.7   9.6
Return on equity (ROE), % 14.9 14.1   11.6
Capital expenditure 21.2 20.8 1.8% 143.6
Cash flow after investing activities 10.3 29.1   83.5
Net debt, EUR million 314.3 383.4   321.7
Net debt/EBITDA 1.19 1.59   1.36
Net gearing, % 57.6 76.2   53.9
Equity ratio, % 45.3 42.6   48.4
Basic earnings per share, EUR 0.16 0.14   0.51
Diluted earnings per share, EUR 0.16 0.14   0.51
Personnel at the end of period 1,684 1,683   1,668

*Group key figures

CEO's review

DNA's year 2017 is off to a strong start as expected. Our net sales increased 5.7% to EUR 213.4 million. Strong growth of service revenue (net sales less sales of devices and interconnection charges) continued, and good development of mobile device sales also had a positive effect on net sales. Service revenue was boosted in particular by the positive development of the mobile subscription base and growing use of mobile data as 4G subscriptions become more common. Our profitability improved and our operating result grew 14.9% and was EUR 28.9 million, or 13.5% of net sales (12.4%).

Mobile communication network subscription volumes were up 100,000 from the reference period. There was a clear improvement in DNA's revenue per user (ARPU) for mobile communications from the comparison period. Price increases in certain older DNA subscription types increased DNA's subscription turnover rate (CHURN) in the first quarter. Our fixed-network subscription base (fixed voice, fixed broadband and cable television) increased by 8,000 subscriptions from the reference period, even though our customers kept moving away from using of fixed-voice subscriptions. At the same time, fixed-network broadband and cable television subscriptions increased in total by 20,000.

In 2017, the focus of our network investments has shifted from network coverage expansion to capacity expansion. At the end of 2016, our 4G network reached 99.6 per cent of the population in mainland Finland as the shared network was completed in Eastern and Northern Finland. Due to the improved coverage, DNA has gained new consumer and corporate customers in the area. For example, the University of Lapland selected DNA as its mobile service provider. The agreement between DNA and the University of Lapland covers mobile voice and data connections for hundreds of users. When selecting the service provider, the University of Lapland placed emphasis on coverage.

The DNA Valokuitu Plus (DNA Fibre Optic Plus) network enables broadband speeds of a Gigabit class per second without any changes to the housing company's internal network. In the first quarter, the Gigabit class speed became available to all 600,000 households in the DNA Valokuitu Plus network across Finland. DNA is among the first operators globally that is capable of providing Gigabit class broadband speeds in the entire network.

In the first quarter, we tested the potential of the new 5G radio technology with Ericsson. A transmission speed of some 25 Gbps and a delay of less than 3 ms were achieved in the radio connection in the 5G test, which is a strong demonstration of the progress of 5G development. There are three important targets for 5G in the future: to enable a large-scale Internet of Things, to support highly reliable delay-critical connections, and to further increase the speed and efficiency of mobile broadband connections.

In the first quarter, we became the first company in Finland to introduce grandparental leave, entitling grandparents to a one week's paid leave.

Competition is expected to remain intense for the rest of the year and our outlook for 2017 remains unchanged. According to our strategy, we will continue measures to improve our customer experience further, and we will also continue to focus on employee well-being and professional development.

Jukka Leinonen President and CEO

Additional information:

Jukka Leinonen, CEO, DNA Plc, tel. +358 44 044 1000, jukka.leinonen(at)dna.fi Timo Karppinen, CFO, DNA Plc, tel. +358 44 044 5007, timo.karppinen(at)dna.fi Marja Mäkinen, Head of IR, DNA Plc, tel. +358 44 044 1262, marja.makinen(at)dna.fi DNA Corporate Communications, tel. +358 44 044 8000, communications(at)dna.fi

DNA's financial publications in 2017:

  • Half Year Financial Report, 18 July 2017 at 8:30 AM
  • Interim Report January-September, 20 October 2017 at 8:30 AM

Distribution: Nasdaq Helsinki Key media www.dna.fi

 

Attachments:

http://www.globenewswire.com/NewsRoom/Attachm...e54ac83bec

Scroll down for more posts ▼

Top 10 Most Recent News Articles

EZaccessMD Data Breach: Class Action Lawsuit Looms

Updated Category News Views 637

Data breaches are the bogeyman no one wants lurking in the shadows, and when it’s your personal info at stake, folks rightfully squirm. This recent fiasco at EZaccessMD is one of those unsettling incidents. The word on the street isn't pretty: sensitive medical data has slipped through the cracks, leaving Edelson Lechtzin LLP, a heavyweight in class action maneuvers, to...

Continue Reading
HONGQI's EHS4 Launch in Europe: Bridging East and West

Updated Category News Views 265

Revving Up a New Chapter: HONGQI in Venice There's a new player in the European automotive scene, and it's rolling in with more style than a Venetian gondola. HONGQI, a name that's been turning gears in China since '58, is packing its suitcases full of Eastern elegance and landing straight in Venice with the all-electric EHS4. On November 16, the brand is set to unveil...

Continue Reading
Uber Data Breach: Class Action Investigation Begins

Updated Category News Views 202

When Tech Meets Trouble: Uber's Data Breach Picture this: the hum of Uber rides weaving through your city, drivers none the wiser that personal info has been pried from the vaults thanks to their tech partner, Fireworks AI. Uber, folks, is in hot water once again. This isn’t just another tech hiccup; it's a legal whirlwind brewing up courtesy of Edelson Lechtzin LLP, a...

Continue Reading
WHO and RCSI Bahrain Join Forces on Health Initiatives

Updated Category News Views 345

Forging a Healthier Pathway In a world where healthcare challenges rise faster than my blood pressure during a stock market crash, the World Health Organization (WHO) and the Royal College of Surgeons in Ireland (RCSI) – Medical University of Bahrain have inked a deal to tackle these issues head-on. The memorandum of understanding (MoU) signed on November 15, 2026,...

Continue Reading
Employment Law Suit Hits ABC: Alleged Wage Violations

Updated Category News Views 60

ABC Under Fire for Labor Code Violations You know it's a rocky road when a company like American Broadcasting Companies, Inc. lands itself in hot water with accusations riding high on labor law violations. People yapping about lunch breaks? Well, that’s the ball game here. Meal and Rest Break Controversies According to a recent lawsuit filed by Blumenthal Nordrehaug...

Continue Reading
JOYEE N01 Debuts Globally with First 2,000 Deliveries

Updated Category News Views 203

JOYYE N01 Breaks into the Global Market Now, here we go, folks—a Chinese car with ambitions bigger than the Sahara. On October 28, the JOYEE N01 rolled off the assembly line and into the international scene with a lot of fanfare at FAW's Yancheng Branch. Mark my words, this isn't just another model trying to strut into the global auto arena. This event delivered the...

Continue Reading
Shenzhen's Vision Unveiled: APEC 2026 Promo Debut

Updated Category News Views 356

Shenzhen's Spotlight Moment at APEC 2026 When Shenzhen announced its promotional video for the 2026 APEC Economic Leaders' Meeting, it wasn't just about standard tourism glitz. This was a show of force, a bold step onto the main stage of global politics and economics. The video's launch wasn’t merely an audio-visual delight—it staked a claim in shaping the future...

Continue Reading
D-Wave Quantum Hit with Securities Fraud Lawsuit

Updated Category News Views 215

A Legal Quagmire for D-Wave Quantum Investors Securities fraud lawsuits are like light in a dark alley—you need them when the truth's been stashed out of sight, but they illuminate the dirty and damp parts of investment strategies nobody wants to talk about. Right now, D-Wave Quantum Inc. is smack dab in the middle of such litigious action. If you had the misfortune of...

Continue Reading
InstaHeat 35K: FOGATTI Offers Upgraded RV Furnace Control

Updated Category News Views 107

Winter RV Trips Just Got Cozier There's nothing quite like hitting the open road in an RV during the winter months. But let's face it, nobody wants to return to a cabin that's as frigid as the great outdoors. Here's where FOGATTI steps up its game with the InstaHeat Ultra 35K RV Furnace. They’ve tinkered with the thermostat to iron out more precise control, just in time...

Continue Reading
CVS Study: GLP-1 Drugs Effective But Costly

Updated Category News Views 42

Can GLP-1s Deliver Value at Their Current Price? Alright, folks, here's a real-world gut check from CVS Health. They crunched some numbers using Aetna's anonymized claims data, and the results are eye-opening. These GLP-1s are showing promising health outcomes—lower hospital visits, better clinical results, yada yada. But when it comes to savings, they ain't quite...

Continue Reading

Top 5 Most Recently Viewed Articles

Li Auto Inc. Reports Record Revenue and Milestone Deliveries

Updated Category News Views 89

Li Auto Inc. Announces Impressive Financial Results In the latest quarter, Li Auto Inc. reported a remarkable total revenue of RMB42.9 billion (approximately US$6.1 billion), showcasing a year-over-year growth of 23.6%. This impressive performance reflects the company's strong market presence and strategic execution. Quarterly Deliveries and Growth In terms of vehicle...

Continue Reading
LifeWallet's $2 Million Settlement and Strategic Progress Ahead

Updated Category News Views 162

LifeWallet's Recent Settlement Progress LifeWallet, formerly known as MSP Recovery, has recently made headlines by announcing a preliminary $2 million settlement as part of its portfolio of pharmaceutical litigation cases. This development is just one part of the company's broader strategy to engage various pharmaceutical and medical device manufacturers. The commitment...

Continue Reading
Revolutionary Approaches to Managing Resistant Hypertension

Updated Category News Views 261

Understanding Resistant Hypertension Resistant hypertension is a significant challenge for many patients, often referred to as the silent killer due to its insidious nature. Many individuals suffering from high blood pressure are unaware they have it, leading to severe health complications like cardiovascular disease over time. With the upcoming World Hypertension Day,...

Continue Reading
Understanding Wipro's Anticipated Earnings Performance

Updated Category News Views 51

Understanding Wipro's Anticipated Earnings Performance Wipro (WIT) is poised to release its latest quarterly earnings shortly. Investors are eager to gain insights from this upcoming report, which is shaping up to be a pivotal moment for the company. With analysts estimating an earnings per share (EPS) of $0.07, stakeholders are closely watching for news that could...

Continue Reading
Breakthrough Gene Therapy for Parkinson's Secures FDA Designation

Updated Category News Views 276

Significant FDA Recognition for AB-1005 AskBio Inc., known for its groundbreaking work in gene therapy, has made headlines with the announcement that its investigational gene therapy AB-1005 has received the esteemed Regenerative Medicine Advanced Therapy (RMAT) designation from the United States Food and Drug Administration (FDA). This acknowledgement comes on the heels...

Continue Reading